Summary
Ipriflavone, one of the iprflavone derivatives, is a therapeutic drug for osteoporosis. The mechanism is thought to be the inhibition of bone resorption. In the present paper, we report that ipriflavone inhibited formation of osteoclasts from murine spleen cells co-cultured with stromal cells cloned from murine bone marrow. In this system, ipriflavone inhibited osteoclast generation in a dose-dependent manner (10−7-10−5 M). Ipriflavone also inhibited prostaglandin E2 production in MC3T3-E1 cells, which are widely employed as osteoblasts. Moreover, ipriflavone inhibited the proliferation of stromal cells (10−6-10−5 M), but not osteoblastic cells. These results suggest that one mechanism for the inhibitory effects of ipriflavone on bone resorption is the inhibition of osteoclast formation through inhibiting prostaglandin E2 production in osteoblasts and thereby suppressing proliferation of stromal cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M (1986) Effect of ipriflavone on glucocorticoidinduced osteoporosis in rats. Life Sci 38:951–958
Yamazaki I, Shino A, Tsukuda R (1986) Effect of iproflavone on osteoporosis induced by ovariectomy in rats. J Bone Miner Metab 3:205–210
Shinto A, Matsuo T, Tsuda M, Yamazaki I, Tsukuda R, Kitazaki T, Shiota K, Okada H, Yoshida K (1986) Effect of ipriflavone on bone and mineral metabolism in the streptozocin diabetic rats. J Bone Miner Metab 3:27–37
Fujita T, Yoshikawa S, Ono K, Inoue T, Orimo H (1986) Usefulness of TC-89 (ipriflavone) tablets in osteoporosis: multicenter, double-blind, placebo-controlled study. Igakunoayumi (Japan) 138:113–141
Agnusdei D, Dacchei F, Bigazzi S, Cepollaro C, Nardi P, Montagnani M, Gennari C (1989) Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 15:97–104
Yamazaki I (1986) Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci 38:757–764
Yamazaki I, Kinoshita M (1986) Calcitonin secreting property of ipriflavone in the presence of estrogen. Life Sci 38:1535–1541
Tsuda M, Kitazaki T, Ito T, Fujita T (1986) The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1:207–211
Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T (1988) Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600–2602
Kind PRN, King EJ (1954) Estimation of plasma phosphate by determination of hydrolysed phenol with amino-antipyrine. J Clin Pathol 7:322–326
Murota S, Kawamura M, Morita I (1978) Transformation of arachidonic acid into thromboxane B2 by the homogenates of activated macrophages. Biochem Biophys Acta 528:507–511
Morita I, Toriyama K, Murota S (1989) Effect of prostaglandin E2 on phenotype of osteoclast-like cells. Adv Prostaglandin Thromboxane Leukotriene Res 19:419–422
Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987–996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morita, I., Sakaguchi, K., Kurachi, T. et al. Ipriflavone inhibits murine osteoclast formationIn Vitro . Calcif Tissue Int 51 (Suppl 1), S7–S10 (1992). https://doi.org/10.1007/BF02180242
Issue Date:
DOI: https://doi.org/10.1007/BF02180242